Clinical Trial Update: A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating trastuzumab in combination with capecitabine in patients with HER2-positive metastatic or recurrent breast cancer after first-line or (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Xeloda (capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-12-17